Market Overview:
The global myelodysplastic syndrome market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of myelodysplastic syndrome, rising awareness about myelodysplastic syndrome, and the launch of new therapies for the treatment of myelodysplastic syndrome. However, the high cost associated with these therapies is likely to restrain the growth of this market during the forecast period. Based on type, alkylating agents are expected to account for a major share of the global myelodysplastic syndrome market during the forecast period. This can be attributed to their ability to kill cancer cells and induce apoptosis in them.
Product Definition:
Myelodysplastic Syndrome is a progressive bone marrow disorder characterized by the abnormal development of blood cells. The importance of Myelodysplastic Syndrome is that it can lead to leukemia if left untreated.
Alkylating Agents:
Alkylating agents are a group of radionuclides that bind to DNA. The most common alkylating agent is methyl mercury which has the formula (CH3)2Hg. Alkylating agents are used in radiation oncology and chemotherapy for cancer treatment as they kill the cancer cells by causing them to die by forming cross-links between the nucleotides in their genetic material, thereby disrupting their growth and inhibiting cell reproduction.
Cytotoxic Antibiotics:
Cytotoxic antibiotics are antibiotic drugs that kill bacteria by interference with bacterial cell wall synthesis. Some of the common types of antibiotics used for treatment include Amoxicillin/Amoxcillin, Cephalosporin, and Penicillin. These medications are mainly prescribed for bacterial infections but can also be used against fungal infections. The most common side effects associated with these medications include diarrhea, nausea & vomiting, abdominal pain & swelling among others.
Application Insights:
The global market is segmented by application into hospital and clinic settings. The hospital segment dominated the overall market in terms of revenue in 2017, owing to the rising prevalence of cancer and increasing awareness about diagnosis. According to WHO, around 5-10% of patients suffering from blood disorders are diagnosed with myelodysplastic syndrome (MDS) every year. In addition, according to data published by NCBI, around 1% - 2% of all patients develop MDS every year globally as well as across various regions including North America, Europe and Asia Pacific. Thus a large patient base with a high risk factor burden creates demand for treatment options which eventually boosts the growth rate for this application segment over other segments during forecast years.
Clinic settings are expected to witness significant growth over the forecast period due largely on increased R&D initiatives undertaken by private institutions.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some of the factors contributing to its growth. Moreover, approval and commercialization of drugs for treatment options for MGD patients is also expected to drive regional growth over the forecast period. For instance, in May 2018 Fycompa was approved by FDA for use as a single agent or combination therapy with lenalidomide (Revlimid) or thalidomide (Thalimid) in adults with MDS/MCL who have received one prior myeloablative therapy regimen.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to rising healthcare expenditure.
Growth Factors:
- Increasing incidence of myelodysplastic syndrome (MDS) due to aging population and exposure to radiation and chemotherapy.
- Growing demand for better treatment options for MDS patients.
- increasing research funding for development of new therapies for MDS patients.
- rising number of clinical trials being conducted on MDS therapies. 5
Scope Of The Report
Report Attributes
Report Details
Report Title
Myelodysplastic Syndrome Market Research Report
By Type
Alkylating Agents, Cytotoxic Antibiotics, Topoisomerase Inhibitors, Others
By Application
Hospital, Clinic
By Companies
Celgene, Novartis, Otsuka, Actinium Pharmaceuticals, Acceleron Pharma, Bellicum Pharmaceuticals, Cornerstone Pharmaceuticals, CTI BioPharma, Onconova Therapeutics, Strategia Therapeutics, KaloBios Pharmaceuticals, Kiadis Pharma, Mirati Therapeutics, Astex, Celator Pharmaceuticals, Eli-lilly, Sunesis Pharmaceuticals, Targazyme, Gamida Cell, GlaxoSmithKline, Sumitomo Dainippon Pharma, TetraLogic Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Myelodysplastic Syndrome Market Report Segments:
The global Myelodysplastic Syndrome market is segmented on the basis of:
Types
Alkylating Agents, Cytotoxic Antibiotics, Topoisomerase Inhibitors, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Celgene
- Novartis
- Otsuka
- Actinium Pharmaceuticals
- Acceleron Pharma
- Bellicum Pharmaceuticals
- Cornerstone Pharmaceuticals
- CTI BioPharma
- Onconova Therapeutics
- Strategia Therapeutics
- KaloBios Pharmaceuticals
- Kiadis Pharma
- Mirati Therapeutics
- Astex
- Celator Pharmaceuticals
- Eli-lilly
- Sunesis Pharmaceuticals
- Targazyme
- Gamida Cell
- GlaxoSmithKline
- Sumitomo Dainippon Pharma
- TetraLogic Pharmaceuticals
Highlights of The Myelodysplastic Syndrome Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Alkylating Agents
- Cytotoxic Antibiotics
- Topoisomerase Inhibitors
- Others
- By Application:
- Hospital
- Clinic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Myelodysplastic Syndrome Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Myelodysplastic syndrome (MDS) is a rare blood cancer that affects the bone marrow. The disease causes an abnormal increase in the number of white blood cells in the bloodstream. This can make it difficult for your body to fight infections, and can lead to serious health problems. MDS is most commonly caused by a virus or radiation exposure, but it can also be caused by genetic factors or other unknown factors.
Some of the major players in the myelodysplastic syndrome market are Celgene, Novartis, Otsuka, Actinium Pharmaceuticals, Acceleron Pharma, Bellicum Pharmaceuticals, Cornerstone Pharmaceuticals, CTI BioPharma, Onconova Therapeutics, Strategia Therapeutics, KaloBios Pharmaceuticals, Kiadis Pharma, Mirati Therapeutics, Astex, Celator Pharmaceuticals, Eli-lilly, Sunesis Pharmaceuticals, Targazyme, Gamida Cell, GlaxoSmithKline, Sumitomo Dainippon Pharma, TetraLogic Pharmaceuticals.
The myelodysplastic syndrome market is expected to register a CAGR of 5.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Myelodysplastic Syndrome Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Myelodysplastic Syndrome Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Myelodysplastic Syndrome Market - Supply Chain
4.5. Global Myelodysplastic Syndrome Market Forecast
4.5.1. Myelodysplastic Syndrome Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Myelodysplastic Syndrome Market Size (000 Units) and Y-o-Y Growth
4.5.3. Myelodysplastic Syndrome Market Absolute $ Opportunity
5. Global Myelodysplastic Syndrome Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Myelodysplastic Syndrome Market Size and Volume Forecast by Type
5.3.1. Alkylating Agents
5.3.2. Cytotoxic Antibiotics
5.3.3. Topoisomerase Inhibitors
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Myelodysplastic Syndrome Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Myelodysplastic Syndrome Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Myelodysplastic Syndrome Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Myelodysplastic Syndrome Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Myelodysplastic Syndrome Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Myelodysplastic Syndrome Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Myelodysplastic Syndrome Demand Share Forecast, 2019-2026
9. North America Myelodysplastic Syndrome Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Myelodysplastic Syndrome Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Myelodysplastic Syndrome Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Myelodysplastic Syndrome Market Size and Volume Forecast by Type
9.7.1. Alkylating Agents
9.7.2. Cytotoxic Antibiotics
9.7.3. Topoisomerase Inhibitors
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Myelodysplastic Syndrome Demand Share Forecast, 2019-2026
10. Latin America Myelodysplastic Syndrome Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Myelodysplastic Syndrome Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Myelodysplastic Syndrome Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Myelodysplastic Syndrome Market Size and Volume Forecast by Type
10.7.1. Alkylating Agents
10.7.2. Cytotoxic Antibiotics
10.7.3. Topoisomerase Inhibitors
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Myelodysplastic Syndrome Demand Share Forecast, 2019-2026
11. Europe Myelodysplastic Syndrome Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Myelodysplastic Syndrome Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Myelodysplastic Syndrome Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Myelodysplastic Syndrome Market Size and Volume Forecast by Type
11.7.1. Alkylating Agents
11.7.2. Cytotoxic Antibiotics
11.7.3. Topoisomerase Inhibitors
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by ype
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Myelodysplastic Syndrome Demand Share, 2019-2026
12. Asia Pacific Myelodysplastic Syndrome Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Myelodysplastic Syndrome Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Myelodysplastic Syndrome Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Myelodysplastic Syndrome Market Size and Volume Forecast by Type
12.7.1. Alkylating Agents
12.7.2. Cytotoxic Antibiotics
12.7.3. Topoisomerase Inhibitors
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Myelodysplastic Syndrome Demand Share, 2019-2026
13. Middle East & Africa Myelodysplastic Syndrome Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Myelodysplastic Syndrome Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Myelodysplastic Syndrome Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Myelodysplastic Syndrome Market Size and Volume Forecast by Type
13.7.1. Alkylating Agents
13.7.2. Cytotoxic Antibiotics
13.7.3. Topoisomerase Inhibitors
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Myelodysplastic Syndrome Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Myelodysplastic Syndrome Market: Market Share Analysis
14.2. Myelodysplastic Syndrome Distributors and Customers
14.3. Myelodysplastic Syndrome Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Celgene
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novartis
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Otsuka
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Actinium Pharmaceuticals
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Acceleron Pharma
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Bellicum Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Cornerstone Pharmaceuticals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. CTI BioPharma
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Onconova Therapeutics
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Strategia Therapeutics
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. KaloBios Pharmaceuticals
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Kiadis Pharma
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Mirati Therapeutics
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Astex
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Celator Pharmaceuticals
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Eli-lilly
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Sunesis Pharmaceuticals
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Targazyme
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Gamida Cell
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. GlaxoSmithKline
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
